Th17 and th1 T-cell responses in giant cell arteritis

Circulation

Volumn 121, Issue 7, 2010, Pages 906-915

  Deng, Jiusheng ^a,c   Younge, Brian R ^b   Olshen, Richard A ^c   Goronzy, Jörg J ^a,c   Weyand, Cornelia M ^a,c  

^a EMORY UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Glucocorticoids; Inflammation; Interferons; Interleukin 17; Th1 cells; Vasculitis

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; PREDNISONE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD VESSEL BIOPSY; CHIMERA; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENGRAFTMENT; FLOW CYTOMETRY; GIANT CELL ARTERITIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TEMPORAL ARTERY; TH1 CELL; TH17 CELL;

ANIMALS; CHIMERA; DISEASE MODELS, ANIMAL; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; TH1 CELLS;

EID: 77649157249     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.872903     Document Type: Article

References (38)

1. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheu-matica. Ann Intern Med. 2003;139:505-515.
2. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med. 1995;122:502-507.
3. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621-630.
4. Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, Cimmino M, Gerli R, Catanoso MG, Boiardi L, Cantini F, Klersy C, Hunder GG. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007;146:631-639.
5. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, Merkel PA. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789-2797.
6. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310-3318.
7. Stone JH. Antiplatelet versus anticoagulant therapy in patients with giant cell arteritis: which is best? Nat Clin Pract Rheumatol. 2007;3:136-137.
8. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum. 2002;46:457-466.
9. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120:987-992.
10. Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest. 1997;99:2842-2850.
11. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041-1048.
12. Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med. 2003;349:160-169.
13. Weyand CM, Younge BR, Goronzy JJ. T cells in arteritis and atherosclerosis. Curr Opin Lipidol. 2008;19:469-477.
14. Krupa WM, Dewan M, Jeon MS, Kurtin PJ, Younge BR, Goronzy JJ, Weyand CM. Trapping of misdirected dendritic cells in the granulo-matous lesions of giant cell arteritis. Am J Pathol. 2002;161:1815-1823.
15. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004;199:173-183.
16. Deng J, Ma-Krupa W, Gewirtz AT, Younge BR, Goronzy JJ, Weyand CM. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res. 2009;104:488-495.
17. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation. 2008;118:1276-1284.
18. Weyand CM, Schonberger J, Oppitz U, Hunder NN, Hicok KC, Goronzy JJ. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med. 1994;179:951-960.
19. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484-491.
20. Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum. 1997;40:19-26.
21. Kaiser M, Younge B, Bjornsson J, Goronzy JJ, Weyand CM. Formation of new vasa vasorum in vasculitis: production of angiogenic cytokines by multinucleated giant cells. Am J Pathol. 1999;155:765-774.
22. Wagner AD, Bjornsson J, Bartley GB, Goronzy JJ, Weyand CM. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol. 1996;148:1925-1933.
23. Nordborg C, Larsson K, Nordborg E. Stereological study of neovascu-larization in temporal arteritis. J Rheumatol. 2006;33:2020-2025.
24. Rodriguez-Pla A, Bosch-Gil JA, Rossello-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-Tarres M. Metalloproteinase-2 and-9 in giant cell arteritis: involvement in vascular remodeling. Circulation. 2005;112: 264-269.
25. Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res. 2008;41:87-102.
26. Cantini F, Niccoli L, Nannini C, Bertoni M, Salvarani C. Diagnosis and treatment of giant cell arteritis. Drugs Aging. 2008;25:281-297.
27. Langford CA. Vasculitis in the geriatric population. Rheum Dis Clin North Am. 2007;33:177-195.
28. Seo P, Stone JH. Large-vessel vasculitis. Arthritis Rheum. 2004;51: 128-139.
29. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum. 1999;42:844-853.
30. Rittner HL, Hafner V, Klimiuk PA, Szweda LI, Goronzy JJ, Weyand CM. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest. 1999;103:1007-1013.
31. Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis: evidence for two components of the disease. J Clin Invest. 1994;94:1134-1140.
32. Weyand CM, Wagner AD, Bjornsson J, Goronzy JJ. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest. 1996;98:1642-1649.
33. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheu-matica and giant cell arteritis. Arthritis Rheum. 1993;36:1286-1294.
34. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev. 2008;226:132-146.
35. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008; 8:337-348.
36. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Sgambellone NM, Chan CC, Caspi RR. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008;205:799-810.
37. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173-1175.
38. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F, Mfarrej B, Donnarumma M, Habicht A, Clarkson MR, Iacomini J, Glimcher LH, Sayegh MH, Ansari MJ. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med. 2008;205: 3133-3144.